Every fall, Prime Therapeutics (Prime) publishes a special edition of its triannual report with a dedicated focus on cancer—one of the most pressing and complex challenges in health care. The Fall 2025 Prime Therapeutics Report delivers on that commitment, offering a deep and timely exploration of the innovations, partnerships, and strategies that are reshaping oncology management.  

Among the standout perspectives is an article by Simone Ndujiuba, PharmD, BCOP, clinical oncology pharmacist senior principal for Prime, titled “Reimagining oncology management,” which explores how Prime is helping payers and pharmaceutical partners navigate the evolving landscape of cancer care. 

Why this report matters 

Cancer touches nearly every family, every community and every corner of the health care system. That’s why Prime dedicates this annual fall report to oncology — bringing together insights from industry experts, clients and internal leaders to spotlight what’s working, what’s changing and what’s next. 

This year’s report includes: 

• Client perspectives on improving access to high-cost oncology therapies. 

• Featured articles from industry partners exploring new treatment pathways. 

• Prime-led innovations in benefit design, data analytics and patient support. 

Together, these perspectives paint a picture of a health care ecosystem striving for smarter, more compassionate cancer care. 

Simone Ndujiuba’s vision: Smarter oncology management 

Ndujiuba’s article focuses on how Prime is leading the charge in oncology innovation. Key takeaways include: 

• Smarter benefit design 
  Prime is helping health plans build oncology benefits that balance clinical effectiveness with financial sustainability — helping to ensure patients get timely access to the right treatments. 

• Real-world evidence 
  By leveraging real patient data, Prime identifies trends and outcomes that guide better decision-making across the care continuum. 

• Collaborative partnerships 
  Prime works closely with pharmaceutical companies and payers to align on value, affordability and outcomes — making innovation more accessible. 

• Patient-centered strategy 
  At the heart of Prime’s approach is a commitment to supporting patients through every step of their cancer journey. 

Read Simone Ndujiuba’s full article and dive into the Fall 2025 Prime Therapeutics Report.